CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells

被引:124
作者
Watanabe, Tomoko
Masuyama, Jun-ichi
Sohma, Yoshiaki
Inazawa, Hiroko
Horie, Kaori
Kojima, Kumiko
Uemura, Yasunori
Aoki, Yumi
Kaga, Shuji
Minota, Seiji
Tanaka, Toshiyuki
Yamaguchi, Yasunori
Kobayashi, Tetsuto
Serizawa, Isao
机构
[1] Kirin Brewery Co Ltd, Div Pharmaceut, Cellular Immunotherapy Pharmaceut Res Labs, Takasaki, Gumma 3701295, Japan
[2] Jichi Med Sch, Dept Med, Div Rheumatol & Clin Immunol, Minami Kawachi, Tochigi 3290498, Japan
[3] Showa Univ, Dept Med 1, Tokyo 1428555, Japan
[4] Osaka Univ, Grad Sch Med, Lab Mol & Cellular Recognit, Suita, Osaka 5650871, Japan
关键词
human; T cells; regulatory T cells; suppressor T cells;
D O I
10.1016/j.clim.2006.05.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We previously reported that 4C8 monoclonal antibody (mAb) provides a costimulatory signal to human CD4(+) T cells and consequently induces regulatory T (Treg) cells, which are hypo-responsive and suppress the polyclonal response of bystander CD4(+) cells in a contact-dependent manner. In this study, we identified the antigen of 4C8 mAb as CD52. Costimulation with Campath-1H, a humanized anti-CD52 mAb, also induced Treg cells. Anti-CD52-induced Treg cells suppressed the proliferation of both CD4(+) and CD8(+) T cells provided with polyclonal or allogeneic stimulation. When Treg cells were induced from Staphylococcal enterotoxin B (SEB) treated cells, they suppressed the response to SEB more efficiently than that to another superantigen, SEA. Furthermore, anti-CD52-induced Treg cells could be expanded by culture with IL-2 followed by CD52-costimulation, and co-injection of expanded Treg cells suppressed lethal xenogeneic graft versus host disease (GvHD) reactions in SCID mice caused by human peripheral blood mononuclear cells (PBMCs). (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:247 / 259
页数:13
相关论文
共 70 条
[1]   The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs [J].
Allan, SE ;
Passerini, L ;
Bacchetta, R ;
Crellin, N ;
Dai, MY ;
Orban, PC ;
Ziegler, SF ;
Roncarolo, MG ;
Levings, MK .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (11) :3276-3284
[2]   In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines [J].
Barrat, FJ ;
Cua, DJ ;
Boonstra, A ;
Richards, DF ;
Crain, C ;
Savelkoul, HF ;
de Waal-Malefyt, R ;
Coffman, RL ;
Hawrylowicz, CM ;
O'Garra, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (05) :603-616
[3]   Neuropilin-1: a surface marker of regulatory T cells [J].
Bruder, D ;
Probst-Kepper, M ;
Westendorf, AM ;
Geffers, R ;
Beissert, S ;
Loser, K ;
von Boehmer, H ;
Buer, J ;
Hansen, W .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (03) :623-630
[4]   Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients [J].
Calne, R ;
Moffatt, SD ;
Friend, PJ ;
Jamieson, NV ;
Bradley, JA ;
Hale, G ;
Firth, J ;
Bradley, J ;
Smith, KGC ;
Waldmann, M .
TRANSPLANTATION, 1999, 68 (10) :1613-1616
[5]   Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3 [J].
Chen, WJ ;
Jin, WW ;
Hardegen, N ;
Lei, KJ ;
Li, L ;
Marinos, N ;
McGrady, G ;
Wahl, SM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (12) :1875-1886
[6]   CD4+CD25+ immunoregulatory T cells:: New therapeutics for graft-versus-host disease [J].
Cohen, JL ;
Trenado, A ;
Vasey, D ;
Klatzmann, D ;
Salomon, BL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (03) :401-406
[7]   Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis [J].
Coles, AJ ;
Wing, N ;
Smith, S ;
Coraddu, F ;
Greer, S ;
Taylor, C ;
Weetman, A ;
Hale, G ;
Chatterjee, VK ;
Waldmann, H ;
Compston, A .
LANCET, 1999, 354 (9191) :1691-1695
[8]   Ex vivo isolation and characterization of CD4+CD25+ T cells with regulatory properties from human blood [J].
Dieckmann, D ;
Plottner, H ;
Berchtold, S ;
Berger, T ;
Schuler, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (11) :1303-1310
[9]   CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation [J].
Edinger, M ;
Hoffmann, P ;
Ermann, J ;
Drago, K ;
Fathman, CG ;
Strober, S ;
Negrin, RS .
NATURE MEDICINE, 2003, 9 (09) :1144-1150
[10]   Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils [J].
Elsner, J ;
Hochstetter, R ;
Spiekermann, K ;
Kapp, A .
BLOOD, 1996, 88 (12) :4684-4693